Background: Travellers' diarrhoea affects tens of millions of people travelling to less developed countries or regions annually. There are positive reports of the use of rifaximin, a non-absorbed, gut-selective antibiotic to prevent travellers' diarrhoea. This study will critically review and analyse clinical trials on the subject. Methods: Using the keywords [diarrhoea OR diarrhoea OR travel*] AND [rifaximin OR xifaxan OR xifaxanta OR normix OR rifagut], a preliminary search on the PubMed and Ovid databases yielded 411 papers published in English between 1 January 1988 and 1 July 2016. Of these, there were only five relevant clinical trials. Results: The clinical trials were double-blind, placebo-controlled, randomized trials with a total of 879 subjects. The meta-analysis found significant reduction in risk of travellers' diarrhoea with rifaximin use compared to placebo (pooled RR 0.478, 95% CI: 0.375-0.610, and P < 0.001). For the entire travel and follow-up period, the risk of developing travellers' diarrhoea was significantly greater in individuals receiving the placebo than those receiving rifaximin (daily doses of 400-600 mg). Overall, rifaximin offered significant protection rates of 48-72%, with lower protection rates for Asian than Latin American countries. In terms of tolerability, similar rates of adverse events were reported for the rifaximin and placebo group (P > 0.05), with no clinically significant or serious adverse events related to rifaximin use. Conclusions: There is good evidence supporting the use of rifaximin as a chemoprophylactic agent against travellers' diarrhoea, especially in individuals who are at high risk of severe complications from acute infectious diarrhoea. Rifaximin has an excellent tolerability/safety profile and demonstrated efficacy against diarrhoeagenic Escherichia coli and even enteroinvasive bacteria such Campylobacter species. Future studies should study the most effective dosing regimen for rifaximin chemoprophylaxis, as well as profile local antimicrobial resistance/susceptibility data in less developed regions to further guide rifaximin use.
Introduction
Diarrhoea is the most common medical problem faced by the tens of millions of people travelling to less developed tropical and subtropical countries or regions annually. 1 Travellers' diarrhoea affects up to 60% of travellers, 1 and although the disease is usually non-fatal and self-limiting, it can cause significant dehydration, morbidity and disruption to travel itineraries. 2 Furthermore, affected persons may have persistent diarrhoea lasting more than 2 weeks, and post-infectious irritable bowel syndrome has also been reported in 4-31% of affected individuals. 3 The main causative organisms of travellers' diarrhoea are enterotoxigenic Escherichia coli (ETEC), enteroaggregative Escherichia coli (EAEC), Campylobacter jejuni, Salmonella Original article species and Shigella species. [4] [5] [6] Escherichia coli is the main pathogen encountered in Mexico while Campylobacter species are especially prevalent in Southeast Asian countries. Studies have shown that prophylactic antibiotic therapy can prevent a majority of travellers' diarrhoea. 7, 8 However, routine use of prophylactic antibiotic treatment is currently discouraged due to concerns of cost, side effects, alteration of normal gut microbiota and the development of bacterial resistance with indiscriminate antibiotic use. 9 Rifaximin is a poorly water-soluble and minimally absorbed (<0.4%) rifamycin, which exerts its antibacterial effects through inhibition of bacterial RNA synthesis. 10 Rifaximin has good safety/tolerability profile 11 and demonstrated in vitro broad spectrum antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria, including enteric pathogens. 10 It is licensed for treatment of uncomplicated travellers' diarrhoea in the United States. Currently available data also suggest that bacterial resistance is uncommon with rifaximin use, at least for short-term treatment of acute infectious diarrhoea. 12, 13 For these reasons, rifaximin shows great potential for the prevention of travellers' diarrhoea. Renewed interest in the drug has led to several recent clinical trials and studies, and an updated meta-analysis on the subject is hence apt to summarize current evidence and generate hypotheses for future research. The last systematic review on the use of rifaximin contained studies up till January 2010. 14 Full articles were obtained for all selected abstracts and reviewed by all researchers for inclusion. Any disagreement was resolved by discussion and consensus. The inclusion criteria for this review were (i) published randomized controlled trial, (ii) study population involving travellers, (iii) prophylactic administration of a specified dose of rifaximin before travel, (iv) comparison with control (no treatment) or placebo group and (v) available outcome measures for treatment efficacy and safety.
Methods
Methodological quality of the eligible clinical trials was appraised using the Jadad scale 15 by all investigators (consensus). Trials were scored between 0 (very poor) and 5 (rigorous). Cochrane Collaboration's tool for assessing risk of bias 16 of randomized controlled trials was also applied ( Table 2) . The primary outcome measure of interest was the incidence of travellers' diarrhoea in both treatment and control groups, and the safety/incidence of adverse effects related to rifaximin use. Data such as study design, study population, dosage of rifaximin, duration of study and follow-up were extracted and summarized in Table 1 . Risk ratio comparing the incidence of travellers' diarrhoea in the treatment and control group was calculated. Adjusted risk ratios were also used whenever possible. Estimates were pooled and where appropriate, 95% confidence intervals (95% CI) and P values were calculated.
Heterogeneity amongst the different studies pooled was examined using the I 2 statistic and Cochran's Q test. Due to the small number of studies included in the meta-analysis, publication bias was not assessed using a funnel plot or Egger test. All analyses were done using MedCalc Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium; http://www. medcalc.org; 2014).
Results
Of the 411 citations retrieved, 16 full papers were selected for further review. A total of five randomized controlled trials with a total of 879 subjects were included in the final meta-analysis. The abstraction process and reasons for exclusion are illustrated in Figure 1 . All the studies included in the meta-analysis were doubleblind, placebo-controlled, randomized trials, contributing data for three continents. The country of travel included Turkey (Incirlik), Mexico (Guadalajara and Cuernavaca) and South and Southeast Asian countries (India, Nepal, Bangladesh, Sri Lanka, Thailand, Malaysia, Indonesia, Vietnam, Cambodia, Philippines, Myanmar and Laos).
A study 19 had a rather vague description of methodology.
There was no mention of the allocation concealment or randomization methods. Blinding was also not described well. Overall, it may pose a risk of selection, performance and detection biases. A total of 879 patients were included in the five randomized controlled trials comparing rifaximin and placebo for the prevention of travellers' diarrhoea. Fixed-effects and randomeffects models gave similar results. As shown in Figure 2 , the pooled RR of 0.478 (95% CI: 0.375-0.610, P < 0.001) suggests that there is a significant chemoprophylactic effect with rifaximin use. There is a significant reduction in the incidence of travellers' diarrhoea in individuals who received rifaximin than placebo.
Discussion
All available randomized controlled trials (RCTs) support the chemoprophylactic efficacy of rifaximin for travellers' diarrhoea (pooled RR 0.478, 95% CI 0.375-0.610 and P < 0.001). For the entire travel and post-travel (follow-up) period, the risk of developing travellers' diarrhoea was significantly greater in individuals receiving the placebo than those receiving rifaximin (daily doses of 400-600 mg). Overall, rifaximin offered significant protection rates of 48% 21 to 72%. 18 Lower protection rates were seen for travellers visiting Southeast Asia than those visiting South Asia, with highest protection rates for travellers to Mexico. This is attributed to the fact that diarrhoeagenic E. coli is the main pathogen encountered in Mexico [18] [19] [20] while other more invasive pathogens are more commonly found in Asia, including Campylobacter species. 21 In spite of this, the efficacy of rifaximin in preventing travellers' diarrhoea was largely consistent and significant compared to placebo across the different geographical locations and subgroups of individuals infected with diarrhoeagenic E. coli (including ETEC and EAEC), [17] [18] [19] [20] Campylobacter spp., 21 and other unidentified pathogens. [17] [18] [19] [20] [21] With regard to the safety/tolerability profile of rifaximin, all RCTs reported similar rates of adverse events between the rifaximin group and the placebo group, with no statistically significant difference between the two (P > 0.05). [17] [18] [19] [20] [21] In fact, in an adequately powered, double-blind, placebo-controlled trial, it was found that individuals who received 400 mg rifaximin for 28 days had fewer episodes of nausea, abdominal pain, and heartburn than did those who received placebo. 21 Rifaximin appears well tolerated with no clinically significant or serious adverse events related to its use. It is a general concern that bacterial resistance may emerge with widespread antibiotic use. Rifaximin is a non-absorbable, gut-selective antibiotic, largely undetectable in the systemic circulation. 22 Resistance to rifaximin mainly results from mutations in the rpoB gene that encodes the b-subunit of RNA polymerase, leading to potential cross-resistance to all rifamycins. 23 However, studies investigating rifaximin resistance in traveller's diarrhoea-associated E. coli have generally found no clinically significant resistance. 24 Unlike systemically absorbed antibiotics, the local concentration of rifaximin in the gut will easily overwhelm bacterial resistance, making it more difficult for bacteria to acquire resistance to rifaximin. 24 A study using rat models also found that gut Staphylococcal spp. did not develop increasing resistance to rifampicin after a 10-day course of rifaximin. 13 Resistant strains also appeared unstable and unable to replicate in sufficient numbers to colonize the gut. 10 A recent study also found that E. coli and other enteropathogenic bacteria isolated from travellers returning to the United Kingdom were highly susceptible to rifaximin in vitro, compared to alternative antibiotics prescribed for travellers' diarrhoea, notably ciprofloxacin and azithromycin. 25 Importantly, rifaximin also does not appear to significantly alter the normal gastrointestinal flora, as shown in in vitro or ex vivo rat models 13 and in humans. 26, 27 In healthy volunteers, gastrointestinal flora recovered within 1-2 weeks after stopping rifaximin therapy. 27 Routine use of chemoprophylaxis for travellers' diarrhoea is currently discouraged due to concerns of side effects, alteration of normal gut microbiota and the development of bacterial resistance with widespread antibiotic use; however, rifaximin seems to alleviate these concerns. Chemoprophylaxis with rifaximin may be especially reasonable and necessary in high-risk populations, for example, the very old, as well as very sick individuals who are unable to tolerate the effects and dehydration from even mild diarrhoea. Individuals who are immune suppressed may also suffer fatal bacteraemia from a simple gut infection, making chemoprophylaxis life-saving.
The limitations of this meta-analysis must be addressed. Due to the small number of studies, potential publication bias could not be assessed with the use of a funnel plot and Egger test. The generalizability of these findings may also be limited by the fact 
Conclusion
There is good evidence that rifaximin significantly reduces the risk of travellers' diarrhoea. Rifaximin has an excellent tolerability/safety profile and demonstrated efficacy against diarrhoeagenic E. coli and even enteroinvasive bacteria such Campylobacter spp. (albeit higher doses may be needed). Given current best evidence, rifaximin should be considered as an effective and safe option for the prevention of travellers' diarrhoea, especially in high-risk populations e.g. the elderly, immunosuppressed individuals or those with significant underlying medical conditions. Future studies should study the most effective dosing regimen for rifaximin chemoprophylaxis, as well as profile local antimicrobial resistance/susceptibility data in less developed regions to further guide rifaximin use.
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